A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors

F. E. Stuurman, Martijn P. Lolkema, Alwin D. R. Huitema, P. M. M. B. Soetekouw, Hilde Rosing, L. Rolfe, P. Kaur, Jos H. Beijnen, H. van Tinteren, E.E. Voest, Jan H. M. Schellens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)878-883
JournalJournal of Clinical Pharmacology
Volume53
Issue number8
DOIs
Publication statusPublished - Aug 2013

Keywords

  • gemcitabine
  • CO-101
  • CP-4126
  • bioequivalence
  • QT
  • QTc intervals
  • dFdC
  • dFdU
  • phase 1
  • lipid
  • phospholipids
  • cancer
  • formulation
  • infusion

Cite this

Stuurman, F. E., Lolkema, M. P., Huitema, A. D. R., Soetekouw, P. M. M. B., Rosing, H., Rolfe, L., Kaur, P., Beijnen, J. H., van Tinteren, H., Voest, E. E., & Schellens, J. H. M. (2013). A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors. Journal of Clinical Pharmacology, 53(8), 878-883. https://doi.org/10.1002/jcph.108